Business Description
Keros Therapeutics Inc
NAICS : 325412
SIC : 2833
99 Hayden Avenue, Suite 120, Building E, Lexington, MA, USA, 02421
Description
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 321.82 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 38.42 | |||||
| Beneish M-Score | 180.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -8.6 | |||||
| 3-Year EBITDA Growth Rate | -140.8 | |||||
| 3-Year EPS without NRI Growth Rate | -156.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.16 | |||||
| 9-Day RSI | 69.02 | |||||
| 14-Day RSI | 65.51 | |||||
| 6-1 Month Momentum % | -43.79 | |||||
| 12-1 Month Momentum % | -16.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.39 | |||||
| Quick Ratio | 14.39 | |||||
| Cash Ratio | 13.95 | |||||
| Days Sales Outstanding | 165.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -39.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -399.59 | |||||
| Net Margin % | -393.45 | |||||
| ROE % | -34.76 | |||||
| ROA % | -33.05 | |||||
| ROIC % | -970.3 | |||||
| ROC (Joel Greenblatt) % | -1764.77 | |||||
| ROCE % | -33.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 46.23 | |||||
| PB Ratio | 4.56 | |||||
| Price-to-Tangible-Book | 4.56 | |||||
| EV-to-EBIT | -10.44 | |||||
| EV-to-EBITDA | -10.52 | |||||
| EV-to-Revenue | 40.03 | |||||
| EV-to-Forward-Revenue | 50.79 | |||||
| EV-to-FCF | -13.56 | |||||
| Price-to-Net-Current-Asset-Value | 4.66 | |||||
| Price-to-Net-Cash | 4.81 | |||||
| Earnings Yield (Greenblatt) % | -9.58 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:KROS
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20 | ||
| EPS (TTM) ($) | -3.31 | ||
| Beta | 0 | ||
| Volatility % | 67.39 | ||
| 14-Day RSI | 65.51 | ||
| 14-Day ATR ($) | 2.847384 | ||
| 20-Day SMA ($) | 33.003 | ||
| 12-1 Month Momentum % | -16.38 | ||
| 52-Week Range ($) | 24.38 - 68.29 | ||
| Shares Outstanding (Mil) | 25.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Keros Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||